Cingulate is trading at $4.85, up 6.46% in pre-market, with broader healthcare-sector strength providing context but no company-specific catalyst identified. - No Cingulate-specific announcement explaining the November 5 pre-market move surfaced; its press-release page lists no November 5 release. - Context reports XLV up 1.55% pre-market; recent coverage links healthcare-share gains to expectations after the Democratic midterm sweep. - This is sector context, not evidence of a direct catalyst; Cingulate’s pre-market volume or activity level was unavailable.